Evidence map›Paper›PMID 32912190›Full record

ArticleBMC public health2020

Targeted vaccination campaigns of teenagers after two clusters of B invasive meningococcal disease in Brittany, France, 2017.

Mathilde Pivette, Muhamed-Kheir Taha, Anne-Sophie Barret, Elisabeth Polard, Marie-Bernadette Hautier, Jean-Benoît Dufour, Marlène Faisant, Lisa Antoinette King, Denise Antona, Daniel Levy-Bruhl and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Mathilde PivetteSanté publique France, French national public health agency, Direction des régions, Cellule Bretagne, Rennes, France. mathilde.pivette@santepubliquefrance.fr.ORCID http://orcid.org/0000-0002-1867-1561
Muhamed-Kheir TahaInstitut Pasteur, National Reference Center for Meningococci, Paris, France.
Anne-Sophie BarretSanté publique France, French national public health agency, Direction des maladies infectieuses, Saint-Maurice, France.
Elisabeth PolardPharmacovigilance, Pharmacoepidemiology and Drug Information Center, Rennes University Hospital, Rennes, France.
Marie-Bernadette HautierDirection académique de l'Education Nationale, School Health services, Saint-Brieuc, France.
Jean-Benoît DufourAgence régionale de santé Bretagne, Regional health agency, Rennes, France.
Marlène FaisantSanté publique France, French national public health agency, Direction des régions, Cellule Bretagne, Rennes, France.
Lisa Antoinette KingSanté publique France, French national public health agency, Direction des régions, Cellule Bretagne, Rennes, France.
Denise AntonaSanté publique France, French national public health agency, Direction des maladies infectieuses, Saint-Maurice, France.
Daniel Levy-BruhlSanté publique France, French national public health agency, Direction des maladies infectieuses, Saint-Maurice, France.
Hélène TillautSanté publique France, French national public health agency, Direction des régions, Cellule Bretagne, Rennes, France.
Alexandre ScanffSanté publique France, French national public health agency, Direction des régions, Cellule Bretagne, Rennes, France.
Camille MorivalPharmacovigilance, Pharmacoepidemiology and Drug Information Center, Rennes University Hospital, Rennes, France.
José-Hector Aranda GrauAgence régionale de santé Bretagne, Regional health agency, Rennes, France.
Pierre GuillaumotAgence régionale de santé Bretagne, Regional health agency, Rennes, France.
Bertrand GagnièreSanté publique France, French national public health agency, Direction des régions, Cellule Bretagne, Rennes, France.
Santé Publique France · FRAgence Régionale de Santé Ile-de-France · FRCentre Hospitalier Universitaire de Rennes · FRInstitut Pasteur · FRMinistere de l'Education Nationale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn December 2016, three cases of serogroup B invasive meningococcal disease, including two children from the same middle school (11 to 15 years old pupils), occurred in the department (administrative district) Côtes-d'Armor (Brittany, France). They were infected by a rare strain (B:P1.7-2,4:F5-9:cc162), covered by the 4CMenB vaccine (Bexsero®). Four months later, two cases due to the same strain occurred in a high school in the same area (15 to 19 years old students). In accordance with French recommendations, vaccination was proposed to students of both schools and to all individuals aged 11-19 years living or studying in the hyperendemic area. We describe these vaccination campaigns, from the alert to the impact evaluation.

methodsThe target population included 8884 people: 579 in the middle school, 2007 in the high school and 6298 in the community. In both schools, vaccination sessions were organized directly on site. In the community, teenagers were vaccinated by general practitioners. The vaccination campaign took place from May to October 2017. An active pharmacovigilance follow-up was set up to document adverse effects of the vaccine.

resultsConsidering the whole target population, the vaccination coverage was estimated at 43% for 1 dose and 34% for 2 doses. Higher vaccination coverage was observed in the schools (79% in the middle school and 42% in the high school for 2 doses) than in the community (27% for 2 doses). The reported adverse effects were consistent with the safety profile of the vaccine and no severe adverse effect was reported.

conclusionsThis vaccination campaign was the third one implemented with Bexsero® in France and constitutes a reproducible approach for future targeted vaccination campaigns. No additional cases of the same strain have occurred since the end of the campaigns in the area.

Indexed as

Meningococcal InfectionsMeningococcal VaccinesNeisseria meningitidis, Serogroup BAdolescentAdultChildFranceHumansImmunization ProgramsInfantVaccinationYoung AdultMeningococcal VaccinesAdolescentFranceSerogroup B meningitisVaccination campaign

Identifiers

PMID32912190
PMCPMC7488129
OpenAlexW3085373236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.